Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Triple Negative Breast Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms 1 Meningioma 1 Malignant Female Reproductive System Neoplasm 1 Hemangiosarcoma 1 Fallopian Tube Neoplasms 1 Ependymoma 1 Endometrial Neoplasms 1 Disease Progression 1 Colonic Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 5 lutetium Lu 177 dotatate 4 Specimen Handling 4 Radiosurgery 3 gallium Ga 68 dotatate 2 Ga(III)-DOTATOC 2 Bevacizumab 2 regorafenib 1 pembrolizumab 1 olaparib 1 neratinib 1 capivasertib 1 cabozantinib 1 brigatinib 1 abemaciclib 1 X-Rays 1 Watchful Waiting 1 Tablets 1 Surveys and Questionnaires 1 Sunitinib 1 Radiotherapy, Intensity-Modulated 1 Protons 1 Proton Therapy 1 Photons 1 Observation 1 ONC206 1 Nivolumab 1 Mental Status and Dementia Tests 1 Lysine 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Meningioma × neratinib × 90 days × Clear all

NCT04374305 2026-05-06

INTUITT-NF2

Massachusetts General Hospital

Phase 2 Recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡